Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure

被引:8
|
作者
Gerhard, T
Zineh, I
Winterstein, AG
Hartzema, AG
机构
[1] Univ Florida, Dept Pharm Hlth Care Adm, Gainesville, FL 32610 USA
[2] Univ Florida, Dept Pharm Practice, Coll Pharm, Gainesville, FL 32610 USA
[3] Univ Florida, Ctr Pharmacogenom, Gainesville, FL 32610 USA
来源
PHARMACOTHERAPY | 2006年 / 26卷 / 01期
关键词
nesiritide; dobutamine; heart failure; cost-effectiveness; pharmacoeconomics; outcomes;
D O I
10.1592/phco.2006.26.1.34
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To model the cost-effectiveness of nesiritide compared with dobutamine in patients with decompensated heart failure. Design. Cost-effectiveness analysis. Measurements and Main Results. A decision tree model was derived from randomized clinical trial data and data from a previously published economic study. Four cost-effectiveness analyses were performed: analysis 1-full probabilistic analysis, repeatedly sampled probabilities for 6-month mortality and hospital readmission from distributions based on 95% confidence intervals (CIs); analysis 2-best-case nesiritide analysis, used the limiting values of the 95% CI favorable to nesiritide; analysis 3-best-case dobutamine analysis, used the limiting values of the 95% CI favorable to dobutamine; and analysis 4-replicated the previously published cost-effectiveness study and served as a methodologic control. Fifty-one consecutive Monte Carlo simulations for cohorts of 1000 hypothetical patients were performed for each analysis. Incremental cost, incremental effectiveness, and incremental cost-effectiveness ratios (ICERs) were calculated for nesiritide versus dobutamine. Analysis 1 showed a mean ICER of $767/life-year gained for nesiritide versus dobutamine (incremental cost $251 +/- $290, incremental effectiveness 0.33 +/- 0.22 yr). The 95% confidence region surrounding this point estimate spanned all four quadrants of the incremental cost-effectiveness scatterplot, suggesting inconclusive results. Nesiritide was the dominant treatment strategy in analysis 2 (incremental cost -$734 +/- $106, incremental effectiveness 1.19 +/- 0.07 yrs), whereas dobutamine was dominant in analysis 3 (incremental cost $1242 +/- $73, incremental effectiveness -0.57 +/- 0.05 yr). Analysis 4 was comparable to the previously published cost-effectiveness analysis (incremental cost -$77 +/- $87, incremental effectiveness 0.48 +/- 0.05 yr). Conclusions. Based on available randomized clinical trial data, nesiritide did not exhibit robust economic superiority over dobutamine. When incorporating the uncertainty (i.e., 95% CIs) in clinical effectiveness as reported in available clinical trial data into the economic analysis, either nesiritide or dobutamine may be the dominant treatment (i.e., more effective at lower cost) for the studied population. Economic analyses of nesiritide and any comparator must account for uncertainty in estimates of cost as well as in clinical effectiveness.
引用
收藏
页码:34 / 43
页数:10
相关论文
共 50 条
  • [31] Nesiritide vs nitroglycerin for decompensated congestive heart failure - Reply
    Young, JB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (05): : 572 - 573
  • [32] Efficacy and safety of nesiritide in patients with acute decompensated heart failure
    DeWald, Tracy A.
    Hernandez, Adrian F.
    [J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2010, 8 (02) : 159 - 169
  • [33] Levosimendan Plus Dobutamine in Acute Decompensated Heart Failure Refractory to Dobutamine
    Juguet, William
    Fard, Damien
    Faivre, Laureline
    Koutsoukis, Athanasios
    Deguillard, Camille
    Mongardon, Nicolas
    Mekontso-Dessap, Armand
    Huguet, Raphaelle
    Lim, Pascal
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 11
  • [34] Rationale and design of the Pilot Randomized Study of Nesiritide versus Dobutamine in Heart Failure (PRESERVD-HF)
    Gheorghiade, M
    Gattis, WA
    Adams, KF
    Jaffe, AS
    O'Connor, CM
    [J]. AMERICAN HEART JOURNAL, 2003, 145 (02) : S55 - S57
  • [35] Nesiritide in perspective: Evolving approaches to the management of acute decompensated heart failure
    Mills, RM
    Hobbs, RE
    [J]. DRUGS OF TODAY, 2003, 39 (10) : 767 - 774
  • [36] Nesiritide - A brain natriuretic peptide for acutely decompensated congestive heart failure
    Caron, MF
    White, CM
    [J]. FORMULARY, 2001, 36 (09) : 639 - 643
  • [37] Comparison of ultrafiltration, nesiritide, and usual care in acute decompensated heart failure
    Saghir, Syed
    Bartone, Cheryl
    Barrows, Raymond
    Menon, Santosh G.
    Chung, Eugene S.
    [J]. JOURNAL OF CARDIAC FAILURE, 2006, 12 (06) : S118 - S118
  • [38] Clinical experience with prolonged nesiritide infusions in patients with decompensated heart failure
    Ennis, SC
    Ennis, CA
    Ordway, LJ
    Krishnamani, R
    Patten, RD
    DeNofrio, D
    [J]. JOURNAL OF CARDIAC FAILURE, 2004, 10 (04) : S129 - S129
  • [39] Effect of Nesiritide on Renal Function in Patients With Decompensated Diastolic Heart Failure
    Kelesidis, Iosif
    Khullar, Pankaj
    Zhang, Zach
    Vittorio, Timothy
    Zolty, Ronald
    [J]. JOURNAL OF CARDIAC FAILURE, 2010, 16 (08) : S74 - S74
  • [40] Comparison of ultrafiltration to nesiritide therapy as a treatment modality for decompensated heart failure
    Saghir, S
    Bartone, C
    Barrows, R
    Menon, S
    Chung, E
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) : 85A - 85A